These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
206 related articles for article (PubMed ID: 18464570)
1. Insurers and oncologists forge a better cancer drug policy. Butcher L Manag Care; 2008 Apr; 17(4):28-30. PubMed ID: 18464570 [No Abstract] [Full Text] [Related]
2. Reforming the payment system for medical oncology. Bach PB JAMA; 2013 Jul; 310(3):261-2. PubMed ID: 23817729 [No Abstract] [Full Text] [Related]
3. In defense of data. UnitedHealth Group's Ingenix, says data collection unbiased, makes system better. Slavitt A; Ostler D Mod Healthc; 2008 Feb; 38(8):46. PubMed ID: 18491777 [No Abstract] [Full Text] [Related]
4. Healthcare reimbursement for oncology care. Bence S Pa Nurse; 2006 Jun; 61(2):17, 29. PubMed ID: 16871983 [No Abstract] [Full Text] [Related]
5. Reimbursement: current status and future outlook. Bailes JS Semin Oncol; 1994 Aug; 21(4 Suppl 7):118-22. PubMed ID: 8091237 [TBL] [Abstract][Full Text] [Related]
6. Use and coverage of novel cancer agents in managed care. Bailes JS Semin Oncol; 1994 Dec; 21(6 Suppl 14):34-7. PubMed ID: 7992098 [TBL] [Abstract][Full Text] [Related]
7. The economics of managed care reimbursement: a rationale for nonparticipation. DeGroote R Bull Am Coll Surg; 2007 Apr; 92(4):28-36. PubMed ID: 17427590 [No Abstract] [Full Text] [Related]
9. Do the numbers add up for oral oncology quantity-limit programs? McCann T Manag Care; 2013 Jul; 22(7):33-5. PubMed ID: 23936971 [No Abstract] [Full Text] [Related]
10. Navigating the business of oncology for 2008. Crisafulli T Semin Oncol; 2008 Feb; 35(1):1-5. PubMed ID: 18308138 [No Abstract] [Full Text] [Related]
12. Unreasonable charges? Andrews M US News World Rep; 2008 Mar; 144(8):58. PubMed ID: 18435301 [No Abstract] [Full Text] [Related]
13. Value and payment for oncology in the United States. Robinson JC Ann Pharm Fr; 2013 Sep; 71(5):285-90. PubMed ID: 24075699 [TBL] [Abstract][Full Text] [Related]
14. Managed care & medical oncology: the focus is on value. Danielson E; Demartino J; Mullen JA J Natl Compr Canc Netw; 2010 Sep; 8 Suppl 7():S28-37. PubMed ID: 20947721 [TBL] [Abstract][Full Text] [Related]
15. How to create successful alternative payment models in oncology. Miller HD Am J Manag Care; 2017 Apr; 23(5 Spec No.):SP160-SP163. PubMed ID: 28665673 [No Abstract] [Full Text] [Related]
17. Managed care restrictions: barriers to product use in cancer care. Fox LA Am J Manag Care; 2013; 19(1 Spec No):SP24-5. PubMed ID: 23461469 [No Abstract] [Full Text] [Related]
18. L.A.-area oncologists join the march to capitated healthcare. Engstrom P Med Netw Strategy Rep; 1995 May; 4(5):4-5. PubMed ID: 10153139 [No Abstract] [Full Text] [Related]
19. Many new cancer drugs in the United Kingdom are facing negative NICE rulings. Low E; J Clin Oncol; 2007 Jun; 25(18):2635-6; author reply 2637-8. PubMed ID: 17577049 [No Abstract] [Full Text] [Related]
20. Drug sales bring huge profits, and scrutiny, to cancer doctors: insurers and experts see high costs and conflicts. Abelson R N Y Times Web; 2003 Jan; ():A1, 18. PubMed ID: 12647757 [No Abstract] [Full Text] [Related] [Next] [New Search]